This text is a result of machine translation.
Levostar Completes Pre-A Financing Round to Further Invest in CGT
YingHe Neuro Raises Over CNY 100 Mn in Angel Round
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
BlissBio Nets Over CNY 100 Mn in Series B+
Medical Equipment Company PowerSite Nets Over CNY 100 Mn in Series B
Equipment Company Keyto Nets Over CNY 100 Mn in Series C
IVD Company Bioantibody Nets Over CNY 100 Mn in Series A
Taier shares: the contract dispute case against Cao Linbin was accepted by the court
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Yesterday 02:13 PM
Yunnan Baiyao's Revenue Rises 33%; Net Profit Falls 40% in 1Q 2021
On April 27, Yunnan Baiyao released a report for the first quarter of 2021 showing that the company's total operating revenue for the first quarter was 10.33 billion yuan, up 33.4% year-on-year; its operating profit was 880 million yuan, down 41.8% year-on-year; its net profit attributable to shareholders of the listed company was 760 million yuan.
Apr 30, 2021 02:07 AM
Yunnan Baiyao responded that it lost 1.5 billion in stock speculation: it will gradually optimize the structure and gradually withdraw from securities investment
Yunnan Baiyao: An Oriental Mystery in the Limelight (2/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:30 PM
Yunnan Baiyao: An Oriental Mystery in the Limelight (1/2)
Tagged as ‘China’s Time-honored Brand,’ Traditional Chinese Medicine (TCM) company Yunnan Baiyao (000538:SZ) has come to an unprecedented crossroads after fulfilling the challenge of pushing TCM to the foreground.
May 19, 2020 12:00 PM
Wanyi Technology: the net profit in the first three quarters increased by 286.04% to 5.2454 million yuan
August 30 stock market lightning rod
The first bank of China fund to release its second Quarterly Report
Fine Vision Completes Angel Financing Round Worth Nearly CNY 50 Mn